Patient-reported outcomes of cemiplimab versus chemotherapy in advanced NSCLC: PD-L1 level subgroups in EMPOWER-lung 1

Sezer, AhmetGümüş, MahmutBondarenko, Igor NÖzgüroğlu, MustafaGogishvili, MirandaHe, X.Gullo, GuiseppeRietschel, PetraQuek, Ruben Gw2022-11-132022-11-132022Kilickap, S., Sezer, A., Gumus, M., Bondarenko, I., Ozguroglu, M., Gogishvili, M., ... & Quek, R. G. (2022). Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1.1556-08641556-1380https://hdl.handle.net/20.500.12713/3375Patient-reported outcomes of cemiplimab versus chemotherapy in advanced NSCLC: PD-L1 level subgroups in empower-lung 1eninfo:eu-repo/semantics/closedAccessNon-Small Cell Lung CancerPatient-Reported OutcomesCemiplimabPatient-reported outcomes of cemiplimab versus chemotherapy in advanced NSCLC: PD-L1 level subgroups in EMPOWER-lung 1Conference Object179125126WOS:000858678100196Q1